Navigation Links
MannKind Corporation to Hold Third Quarter Financial Results Conference Call on November 5, 2008
Date:10/29/2008

VALENCIA, Calif., Oct. 29 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) will release its 2008 third quarter financial results on Wednesday, November 5, 2008 at 8:00 a.m. EST.

Management of the Company will host a conference call to discuss the third quarter financial results, clinical progress and other Company developments at 9:00 a.m. EST on November 5, 2008. Presenting from the Company will be its Chairman and Chief Executive Officer, Alfred Mann; President and Chief Operating Officer, Hakan Edstrom; Corporate Vice President and Chief Financial Officer, Matthew Pfeffer and Corporate Vice President and Chief Scientific Officer, Peter Richardson.

To participate in the live call by telephone, please dial (888) 677-5721 or (210) 839-8507. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at http://www.mannkindcorp.com.

A telephone replay of the call will be accessible for approximately fourteen days following completion of the call by dialing (866) 411-1707 or (202) 369-0654. A replay will also be available on MannKind's website for fourteen days.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its pipeline includes AFRESA(TM), which has completed Phase 3 clinical trials, and MKC253, which is c
'/>"/>

SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. MannKind Unveils Proposed Trade Name at Dedication of Danbury Manufacturing Facility
2. MannKind to Present at the UBS Global Life Sciences Conference
3. MannKind Corporation Reports Second Quarter Financial Results
4. MannKind Corporation to Hold Second Quarter Financial Results Conference Call on August 11, 2008
5. MannKind to Present at Upcoming Conferences
6. MannKind Corporation Reports First Quarter Financial Results
7. MannKind to Present at the Morgan Stanley Healthcare Conference
8. MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 5, 2008
9. Matthew J. Pfeffer Joins MannKind as Corporate Vice President and Chief Financial Officer
10. MannKind Corporation Response to Recent Market Events
11. MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on March 4, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... February 27, 2015 Immunovaccine Inc. ... immunotherapy company, today announced that the U.S. Food ... Fast Track designation and Phase I clinical trials ... with the mutual co-development agreement signed with Gilead ... Track designation for the DPX-Survivac. , “We have ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 FamilyFarms Group ... General Manager of State Line Farms, received the 2015 ... a producer, under the age of 35, who has ... is an honor to win the Tomorrow's Top Producer ... who won the Top Producer Award and learning from ...
(Date:2/26/2015)... , Feb. 26, 2015 S&P Capital ... Factual Stock Report coverage on MabVax Therapeutics Holdings Inc ... is a clinical stage biotechnology company focused on the ... medical needs in the treatment of cancer. MabVax has ... on the protective immune responses generated by patients who ...
(Date:2/26/2015)... --  Synageva BioPharma Corp. (NASDAQ: ... for rare disorders, today reported 2014 full year ... objectives, and financial guidance.  Synageva,s management team will ... EST to review the financial results and provide ... call by telephone, please dial (877) 445-4603 for ...
Breaking Biology Technology:Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9
... writing a series of articles on raising capital from angel ... Placement Memorandums, or PPMs, and is co-written with Dan Ghoca. ... is necessary to use a private placement memorandum (also referred ... securities to angel investors in a private placement. Once we ...
... on the use of the country's network infrastructure may ... not capture the true essence of the total importance ... economic development. Forget the Digital Divide and view our ... Digital Desert that affects every level of the economic ...
... partner with the law firm Michael Best & Friedrich ... director of government affairs . , , Milwaukee, ... has announced $200 million in new financing for cellulosic ... with projects that may include everything from research and development ...
Cached Biology Technology:When raising capital, why use a Private Placement Memorandum? 2When raising capital, why use a Private Placement Memorandum? 3When raising capital, why use a Private Placement Memorandum? 4When raising capital, why use a Private Placement Memorandum? 5Bridging the digital divide is the wrong battle cry 2Bridging the digital divide is the wrong battle cry 3Bridging the digital divide is the wrong battle cry 4Wisconsin applicants urged to pursue DOE funding for cellulosic biomass 2
(Date:2/18/2015)... (NASDAQ: CPHD ) today announced that its executives ... to participate via webcast. , Cowen and Company Health ... 3, 2015 at 11.20 a.m. Eastern Time , Raymond ... Wednesday, March 4, 2015 at 10.25 a.m. Eastern Time ... these events, please visit Cepheid,s website at http://ir.cepheid.com ...
(Date:2/11/2015)... , February 11, 2015 ... research report "Access Control Market by Product (Cards and ... Residential, Military and Defense, Government, Industrial, Healthcare, Education) and ... published by MarketsandMarkets, the Access Control Market ... 2020, growing at a CAGR of 10.6% ...
(Date:2/5/2015)... 2015  Marken is starting its 35 th ... a new marketing campaign to solidify its place as ... campaign focuses on First as a primary ... The first headline in the series, ... its client,s priorities. Marken recognizes the need to protect ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken Launches New Patient-Centric Campaign 2
... study, "Socioeconomic Conditions Along the World,s Tropical Coasts: 2008," ... healthy coral reefs in 27 tropical nations and points ... decades-old recommendations as a significant barrier to coral reef ... quadrennial "Status of Coral Reefs of the World: 2008" ...
... of the bowel can have genetic causes. Researchers at ... have discovered this correlation. The causes of what is ... most common disorders of the gastrointestinal tract, are considered ... results from Heidelberg, which were published in the prestigious ...
... Michigan State University chemist could eventually lead to a ... are key to treating a number of diseases, including ... manufacture and research often are made within genetically modified ... tends to collect into what scientists call inclusion bodies. ...
Cached Biology News:First-ever socioeconomic study on coral reefs points to challenges of coastal resource management 2First-ever socioeconomic study on coral reefs points to challenges of coastal resource management 3Irritable bowel syndrome can have genetic causes 2
... tested on rat tissue extracts (liver, kidney, spleen, ... cerevisae ) extract. It was also tested with ... lines. Application: A simple and reliable method for ... the detection of the inorganic phosphate released from ...
... the leader in electroporation products and specialty ... product line for experiment optimization and large ... a breakthrough in Molecular Delivery. The days ... that typically limited the number of samples ...
... 20 System revolutionizes DNA sequencing, delivering sequence ... The Genome Sequencer 20 System includes: ... consumables for library construction, amplification, and sequencing ... novo assembly The instrument ...
... RapidVUE is a particle shape and size analyzer ... designed with the utmost simplicity in mind. It ... module and an optical bench. The system is ... easy upgrade for different applications such as dry ...
Biology Products: